Plain-English translation of NCT06058585 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
CAPTIVATE is a large, long-term trial testing whether — a new type of medication — can help slow chronic kidney disease and prevent it from getting worse. The trial is designed to be flexible, meaning researchers can add new treatments or adjust the study as they learn what works best. You would take the medication (or a placebo) for 2 years while researchers carefully monitor your kidney health and safety.
Chronic kidney disease affects hundreds of millions of people worldwide and often leads to kidney failure, heart disease, and early death. Current treatments don't fully prevent these complications, so this trial exists to find out whether this medication can better protect kidney function and improve long-term health outcomes.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic at approximately 1 month, 3 months, 6 months, 12 months, 18 months, and 2 years after starting the medication, with a final visit one month after you stop. At each visit, you'll have blood and urine tests, safety checks, and discussions about how you're doing and whether you're taking the medication as prescribed. The entire treatment phase lasts 2 years, and researchers will also check in on your overall health every 5 years after that.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Australia